Cargando…
Genetic approaches to metabolic bone diseases
Metabolic bone diseases comprise a diverse group of disorders characterized by alterations in skeletal homeostasis, and are often associated with abnormal circulating concentrations of calcium, phosphate or vitamin D metabolites. These diseases commonly have a genetic basis and represent either a mo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533455/ https://www.ncbi.nlm.nih.gov/pubmed/30357886 http://dx.doi.org/10.1111/bcp.13803 |
_version_ | 1783421207117299712 |
---|---|
author | Hannan, Fadil M. Newey, Paul J. Whyte, Michael P. Thakker, Rajesh V. |
author_facet | Hannan, Fadil M. Newey, Paul J. Whyte, Michael P. Thakker, Rajesh V. |
author_sort | Hannan, Fadil M. |
collection | PubMed |
description | Metabolic bone diseases comprise a diverse group of disorders characterized by alterations in skeletal homeostasis, and are often associated with abnormal circulating concentrations of calcium, phosphate or vitamin D metabolites. These diseases commonly have a genetic basis and represent either a monogenic disorder due to a germline or somatic single gene mutation, or an oligogenic or polygenic disorder that involves variants in more than one gene. Germline single gene mutations causing Mendelian diseases typically have a high penetrance, whereas the genetic variations causing oligogenic or polygenic disorders are each associated with smaller effects with additional contributions from environmental factors. Recognition of familial monogenic disorders is of clinical importance to facilitate timely investigations and management of the patient and any affected relatives. The diagnosis of monogenic metabolic bone disease requires careful clinical evaluation of the large diversity of symptoms and signs associated with these disorders. Thus, the clinician must pursue a systematic approach beginning with a detailed history and physical examination, followed by appropriate laboratory and skeletal imaging evaluations. Finally, the clinician must understand the increasing number and complexity of molecular genetic tests available to ensure their appropriate use and interpretation. |
format | Online Article Text |
id | pubmed-6533455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65334552019-09-16 Genetic approaches to metabolic bone diseases Hannan, Fadil M. Newey, Paul J. Whyte, Michael P. Thakker, Rajesh V. Br J Clin Pharmacol Review‐themed Issue Metabolic bone diseases comprise a diverse group of disorders characterized by alterations in skeletal homeostasis, and are often associated with abnormal circulating concentrations of calcium, phosphate or vitamin D metabolites. These diseases commonly have a genetic basis and represent either a monogenic disorder due to a germline or somatic single gene mutation, or an oligogenic or polygenic disorder that involves variants in more than one gene. Germline single gene mutations causing Mendelian diseases typically have a high penetrance, whereas the genetic variations causing oligogenic or polygenic disorders are each associated with smaller effects with additional contributions from environmental factors. Recognition of familial monogenic disorders is of clinical importance to facilitate timely investigations and management of the patient and any affected relatives. The diagnosis of monogenic metabolic bone disease requires careful clinical evaluation of the large diversity of symptoms and signs associated with these disorders. Thus, the clinician must pursue a systematic approach beginning with a detailed history and physical examination, followed by appropriate laboratory and skeletal imaging evaluations. Finally, the clinician must understand the increasing number and complexity of molecular genetic tests available to ensure their appropriate use and interpretation. John Wiley and Sons Inc. 2018-11-28 2019-06 /pmc/articles/PMC6533455/ /pubmed/30357886 http://dx.doi.org/10.1111/bcp.13803 Text en © 2018 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review‐themed Issue Hannan, Fadil M. Newey, Paul J. Whyte, Michael P. Thakker, Rajesh V. Genetic approaches to metabolic bone diseases |
title | Genetic approaches to metabolic bone diseases |
title_full | Genetic approaches to metabolic bone diseases |
title_fullStr | Genetic approaches to metabolic bone diseases |
title_full_unstemmed | Genetic approaches to metabolic bone diseases |
title_short | Genetic approaches to metabolic bone diseases |
title_sort | genetic approaches to metabolic bone diseases |
topic | Review‐themed Issue |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533455/ https://www.ncbi.nlm.nih.gov/pubmed/30357886 http://dx.doi.org/10.1111/bcp.13803 |
work_keys_str_mv | AT hannanfadilm geneticapproachestometabolicbonediseases AT neweypaulj geneticapproachestometabolicbonediseases AT whytemichaelp geneticapproachestometabolicbonediseases AT thakkerrajeshv geneticapproachestometabolicbonediseases |